Skip to main content
. 2017 Jun 23;12(6):e0179798. doi: 10.1371/journal.pone.0179798

Fig 6. KPC34 is more effective than Ara-C when combined with doxorubicin.

Fig 6

  • A) Schema of treatment trial. C57/Bl6 mice were injected with B6-ALL syngeneic leukemia. Upon engraftment as confirmed by bioluminescent imaging, mice were treated with saline by oral gavage and i.p. (S), Ara-C at 7.1 mg/kg i.p. for four days and Dox at 3 mg/kg i.p. for three days (AD), or KPC34 at 20 mg/kg p.o. for four days and Dox at 3 mg/kg i.p. for three days (KD).
  • B) Bioluminescent image of mice 24 hours after the final treatment.
  • C) Kaplan-Meier curves for animals treated with saline, Ara-C + Dox, or KPC34 + Dox.